S
Sanjeev Puri
Publications - 2
Citations - 2030
Sanjeev Puri is an academic researcher. The author has contributed to research in topics: Clopidogrel & Percutaneous coronary intervention. The author has an hindex of 2, co-authored 2 publications receiving 1895 citations.
Papers
More filters
Journal ArticleDOI
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Jean-François Tanguay,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillabower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +18 more
TL;DR: In this paper, the authors evaluated the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after percutaneous coronary intervention (PCI), but a treatment strategy for this issue was not well defined.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillablower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +17 more
TL;DR: Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard- dose clopIDogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.